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Abstract  
Metastatic renal cell cancer is not exceptional in kidney cancer (30% of patients with kidneyl cancer). Its prognosis is particularly severe. However, 
sciatic neuralgia (sciatica) remains an exceptional revealing clinical sign of this disease. The authors report the case of a patient admitted with right 
sciatica as chief complain, leading to the discovery of a renal cell carcinoma. Although uncommon, renal cell carcinoma spine metastasis should be 
included in the differential diagnosis of back pain and sciatica.  
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Introduction 
 
Kidney cancer accounts for 3% of all malignancies in adults and is the third most common urological cancer after prostate and bladder cancers 
[1].The metastatic form is not uncommon (30% of patients with kidney cancer) and the prognosis is particularly severe. The most frequent 
secondary locations of kidney cancers are lung, bone, liver and brain. Many other sites have been described in the literature. Sciatica is a relatively 
rare mode of presentation of renal cell carcinoma. The authors report the case of a patient who consulted for sciatica associated with a mass of 
the right buttocks leading to the discovery of a metastatic renal cell carcinoma.  
  
  
Patient and case report 
 
A 52-year-old male was admitted to the Neurosurgery Department for right leg sciatica with paraesthesia. Clinical examination found a patient in 
relatively good general conditions. However, a mass in the right buttock was noted. The mass was hard, tender but without signs of inflammation. 
There was significant decrease in muscle strength and reflexes of the right leg. A pelvic CT scan (CT) showed a mass of 19 cm in diameter rising 
from the sacroiliac region (bone and soft tissue). It had straight edge, heterogeneous tissue density with osteolysis in the body of the 11th thoracic 
vertebra and invasion of its spinal canal (Figure 1). Abdominal CT showed a 10 cm right upper pole renal mass (Figure 2).  
  
Several  biopsies  of  the  gluteal  mass  were  performed.  Pathology  confirmed  a  renal  cell  carcinoma  (Fuhrman  grade  III).  A  cytoreductive 
nephrectomy  associated  to  a  postoperative  immunotherapy  was  planned  to  our  patient.  An  open  radical  cytoreductive  nephrectomy  was 
performed.  Postoperative  evolution  was  uneventful.  Pathological  examination  later  confirmed  renal  cell  carcinoma.  External  radiotherapy  for 
analgesia in order to improve the quality of life was performed. Postoperative immunotherapy could not be achieved. The patient died six months 
later, in the setting of cancer cachexia.  
  
  
Discussion 
 
Kidney cancer accounts for 3% of all malignancies in adults and is the third most common urological cancer after prostate cancer and bladder 
cancer  [1].  It  is  characterized  by  an  unpredictable  clinical  course.  The  primary  tumor  location  may  be  revealed  by  multiple  metastases,  or 
otherwise remain quiescent for years [2]. On diagnosis, over one third of patients are already in metastatic stage with multiple locations [3]. The 
metastatic disease is not uncommon and is usually associated with a more severe prognosis. The median survival of these patients is about 10 
months.  
  
Synchronous  metastases  (discovered  during  the  identification  of  the  primary  lesion)  in  kidney  cancer  are  often  multiple.  The  most  common 
metastatic sites of renal cancer are the lung (50 to 60% of cases), lymph nodes (15-30%), bone (30-40%), liver (28%), the adrenals (10-15%) 
and brain (10 to 13%). Kidney cancer, specifically clear cell carcinoma can metastasize to all organs [4]. Unusual sites can be achieved such as the 
gastrointestinal  tract,  genital  organs,  retro-peritoneum,  muscles,  skin,  heart,  breast,  head  and  neck,  etc.  [4].  Renal  metastases  have  been 
described in skeletal muscle, with a relatively low incidence on autopsy series (0 to 1.6%). There is no preferential site muscle, any muscle can be 
invaded (masseter, quadriceps, trapezius, biceps, etc.). Often, these metastases were discovered well after the kidney tumor (10 months to 16 
years) [5]. Among those metastatic sites, a clinical presentation with sciatica was an uncommon event.  
  
There are two main routes for the metastatic spread of kidney cancer: the blood (haematogenous) and lymphatic route. The most frequent route 
is haematogenous, leading to the lungs via the renal vein, vena cava and right atrium. This mode of spread cells was observed for pancreatic 
metastases, spleen, intestine and heart, which are, therefore, often preceded by pulmonary metastases [2].  
  
Atypical renal metastasis can be explained by arterial microemboli, but there are some more specific ways of disseminating. Thus, metastases to 
the testicle, spermatic cord, vagina and ovary can be explained by a retrograde spread from the gonadal vein. The existence of a renal vein 
thrombus (left) or inferior vena cava (right), promote the spin-cell tumor in the spermatic vein reflux, as well as the occurrence of varicocele. [6]. 
Time between metastasis and primary tumor varies different depending on the type of organ affected. For example, pancreatic metastases appear 
on average 10 years after the primary tumor and ranged from 1 month to 27 years [7] while intra-thyroid metastases have an average time of 
onset of 6 to 10 years [8]. These metastases can be found at diagnosis (synchronous metastases) or, more rarely, precede the renal tumor in 5% 
of cases [9]. Some locations such as skin, intestines, heart are rarely isolated and are often preceded by other secondary sites. Sometimes 
metastatic patterns is revealed by a paraneoplastic syndrome (anemia, thrombocytopenia, etc.) [10].  
  
When clinical symptoms and imaging data have revealed the secondary location, say its renal origin is sometimes difficult. It is then possible to 
make use of a thin biopsy needle to characterize the origin of the tumor as it was done in our patient.  
  
Metastatic kidney cancer by definition has a poor prognosis with survival rates at 5 years ranging from 7 to 13%. The management of synchronous 
metastases raises several questions concerning the primary role of nephrectomy. The character of synchronous metastases is a factor of poor 
prognosis, compared with asynchronous metastases. Most studies concerned with cytoreductive nephrectomy in patients with metastatic disease 
are retrospective with small patient samples. In these studies, the operative mortality ranged between 0% and 17% with an operative morbidity 
ranging from 13% to 50% and a number of patients unable to receive systemic therapy between 7% and 77% [11]. Our patient was in this setting 
unable to receive immunotherapy. However, the most important argument in favor of cytoreductive nephrectomy in this setting was that reported 
by a prospective, randomized study of the SWOG (Southwest Oncology Group) and EORTC (European Organization for Research and Treatment of 
The Cancer) [12]. They reported a median survival of 13.6 months for nephrectomy plus interferon group vs 7.8 months for interferon alone group 
[12]. But these studies did not report whether cytoreductive nephrectomy should be performed before or after systemic therapy. It is now clear 
that cytoreductive nephrectomy in patients with metastatic disease with a good performance status and easily resectable tumor is a reasonable Page number not for citation purposes  3 
option. The tumor in our case was perfectly résécable allowing us to perform the nephrectomy in good conditions especially with the good 
performance status of our patient. Nevertheless, selection of patients for this procedure should be judicious having in mind that this gesture is not 
curative [13].  
  
Arguments to justify nephrectomy exist; it could lead to spontaneous regression of metastases, it would prevent the onset of symptoms due to the 
primary  lesion,  it  would  allow  the  correction  of  para-neoplastic  syndromes  and  finally  it  would  maximize  the  impact  of  immunotherapy. 
Nevertheless, some arguments against also exist, leading to not recommend nephrectomy: patients are often delayed for immunotherapy, surgery 
having a deleterious effect by inducing a specific immune deficiency [14]. However, it remains important to note that the level I evidence that 
supports cytoreductive nephrectomy is only for patients who will be candidates for adjuvant immunotherapy. Moreover, similar studies do not yet 
exist for targeted therapies [13]. Our patient was scheduled for an adjuvant immunotherapy. However, his general conditions began to deteriorate 
leading to analgesic radiotherapy to relieve him.  
  
The advantage of laparoscopic nephrectomy in this setting was reported in the literature [15]. It has the demonstrated advantage of reducing 
perioperative morbidity and therefore significantly reduces the time between the intervention and the start of systemic therapy. However, this 
technique currently remains conditional on an appropriate selection of patients. Several prognostic factors influence patient survival: age, general 
health, weight loss, time to metastasis from the primary tumor and the number of metastatic sites [16].  
  
  
Conclusion 
 
Metastatic kidney cancer, which has a very negative prognosis, is currently enjoying some interesting developments. New medical approaches 
(targeted therapies) appear promising for the future. However, further studies including those assessing therapeutic options in large samples of 
patients are needed.  
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Figures 
 
Figure 1: TDM showing a right buttocks and iliac fossa mass with destruction of adjacent structures and invasion of the spinal canal in a patient 
who consulted for sciatica leading to the discovery of a renal cell carcinoma 
 
Figure 2: TDM showing a right kidney mass in a patient who consulted for sciatica leading to the discovery of a renal cell carcinoma  
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